QBREXZA

Peak

glycopyrronium

NDATOPICALCLOTH
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT05776927Phase 3Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Started May 2026
304 enrolled
Asthma
NCT07073950Phase 4Recruiting

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

Started Nov 2025
56 enrolled
Chronic Obstructive Pulmonary DiseaseHyperinflation
NCT06712563N/ARecruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Started Apr 2025
2,000 enrolled
Pulmonary Disease, Chronic Obstructive
NCT06723756Phase 1Completed

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

Started Jan 2025
105 enrolled
Healthy Participants
NCT06340581Phase 1Withdrawn

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

Started Oct 2024
0
Healthy

Loss of Exclusivity

LOE Date
Feb 28, 2033
85 months away
Patent Expiry
Feb 28, 2033

Patent Records (5)

Patent #ExpiryTypeUse Code
10052267
Oct 17, 2028
Product
U-2398
8618160
Dec 10, 2029
Product
U-2398
9744105
Jul 18, 2030
Product
U-2398
10548875
Feb 28, 2033
SubstanceProduct
U-2398
10543192
Feb 28, 2033
Product